364 results on '"Iaffaldano P."'
Search Results
152. Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis
- Author
-
Portaccio, Emilio, Fonderico, Mattia, Iaffaldano, Pietro, Pastò, Luisa, Razzolini, Lorenzo, Bellinvia, Angelo, De Luca, Giovanna, Ragonese, Paolo, Patti, Francesco, Brescia Morra, Vincenzo, Cocco, Eleonora, Sola, Patrizia, Inglese, Matilde, Lus, Giacomo, Pozzilli, Carlo, Maimone, Davide, Lugaresi, Alessandra, Gazzola, Paola, Comi, Giancarlo, Pesci, Ilaria, Spitaleri, Daniele, Rezzonico, Marta, Vianello, Marika, Avolio, Carlo, Logullo, Francesco O., Granella, Franco, Salvetti, Marco, Zaffaroni, Mauro, Lucisano, Giuseppe, Filippi, Massimo, Trojano, Maria, and Amato, Maria Pia
- Abstract
IMPORTANCE: Except for ocrelizumab, treatment options in primary progressive multiple sclerosis (PPMS) are lacking. OBJECTIVE: To investigate the effectiveness of DMTs on the risk of becoming wheelchair dependent in a real-world population of patients with PPMS. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, observational, retrospective, comparative effectiveness research study. Data were extracted on November 28, 2018, from the Italian multiple sclerosis register and analyzed from June to December 2021. Mean study follow-up was 11 years. Included in the study cohort were patients with a diagnosis of PPMS and at least 3 years of Expanded Disability Status Scale (EDSS) evaluations and 3 years of follow-up. MAIN OUTCOMES AND MEASURES: The risk of reaching an EDSS score of 7.0 was assessed through multivariable Cox regression models. EXPOSURES: Patients who received DMT before the outcome were considered treated. DMT was assessed as a time-dependent variable and by class of DMT (moderately and highly effective). RESULTS: From a total of 3298 patients with PPMS, 2633 were excluded because they did not meet the entry criteria for the phase 3, multicenter, randomized, parallel-group, double-blind, placebo-controlled study to evaluate the efficacy and safety of ocrelizumab in adults with PPMS (ORATORIO) trial. Among the remaining 665 patients (mean [SD] age, 43.0 [10.7] years; 366 female patients [55.0%]), 409 were further selected for propensity score matching (288 treated and 121 untreated patients). In the matched cohort, during the study follow-up, 37% of patients (152 of 409) reached an EDSS score of 7.0 after a mean (SD) follow-up of 10.6 (5.6) years. A higher EDSS score at baseline (adjusted hazard ratio [aHR], 1.32; 95% CI, 1.13-1.55; P < .001), superimposed relapses (aHR, 2.37; 95% CI, 1.24-4.54; P = .009), and DMT exposure (aHR, 1.75; 95% CI, 1.04-2.94; P = .03) were associated with a higher risk of an EDSS score of 7.0, whereas the interaction term between DMT and superimposed relapses was associated with a reduced risk of EDSS score of 7.0 (aHR, 0.33; 95% CI, 0.16-0.71; P = .004). Similar findings were obtained when treatment according to DMT class was considered and when DMT was included as a time-dependent covariate. These results were confirmed in the subgroup of patients with available magnetic resonance imaging data. CONCLUSIONS AND RELEVANCE: Results of this comparative effectiveness research study suggest that inflammation also occurs in patients with PPMS, may contribute to long-term disability, and may be associated with a reduced risk of becoming wheelchair dependent by current licensed DMTs.
- Published
- 2022
- Full Text
- View/download PDF
153. Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica
- Author
-
Tortorella, C, Ruggieri, M, Di Monte, E, Ceci, E, Iaffaldano, P, Direnzo, V, Mastrapasqua, M, Frigeri, A, Amato, M P, Hakiki, B, Ghezzi, A, Lugaresi, A, De Luca, G, Patti, F, Dʼamico, E, Sola, P, Simone, A M, Svelto, M, Livrea, P, and Trojano, M
- Published
- 2011
- Full Text
- View/download PDF
154. Interrogating large multiple sclerosis registries and databases: what information can be gained?
- Author
-
Trojano, Maria, Kalincik, Tomas, Iaffaldano, Pietro, and Amato, Maria P.
- Published
- 2022
- Full Text
- View/download PDF
155. Effectiveness of Natalizumab on Multiple Sclerosis patients: the Italian registry experience
- Author
-
Chisari, C., Comi, G., Zaffaroni, M., Morra, V. Brescia, Trojano, M., Iaffaldano, P., Cocco, E., Centonze, D., Uccelli, A., Pozzilli, C., Salemi, G., Luca, G., Cottone, S., Millefiorini, E., Salvetti, M., Aguglia, U., Costantino, G., Florio, C., Galgani, S., Pesci, I., Amato, M. P., Rovaris, M., Gazzola, P., Lus, G., Maimone, D., Grimaldi, L. M., Bergamaschi, R., Granella, F., Bertolotto, A., Totaro, R., Vianello, M., Bellantonio, P., Cavalla, P., Di Battista, G., Spitaleri, D., Tedeschi, G., Valzania, F., Scarpini, E., Gatto, M., Valentino, P., Renato Mantegazza, Rezzonico, M., Passarella, B., Avolio, C., Logullo, F. O., Cavalletti, G., Corea, F., Clerico, M., Lugaresi, A., and Patti, F.
- Published
- 2019
156. Variations of Whole–Adria Microplate Motion During the Interseismic Phase Preceding the MW6.3, 6 April 2009 L’Aquila (Italy) Earthquake
- Author
-
Iaffaldano, Giampiero and Kalum, William K.
- Abstract
Tectonic plate motions feed the earthquake cycle—a process whereby stress along crustal faults slowly increases over decade– or century–long periods, to then suddenly drop during earthquakes. Steadiness of plate motions during such cycles has long been a central tenet in models of earthquake genesis and of faults seismic potential, and can be tested against measurements of contemporary plate motions available from Global Navigation Satellite Systems (GNSS). Here we present analyses of GNSS data from Central and Northern Italy that illuminate the motion of the Adria microplate over a period of 6 years preceding the MW6.3, 6 April 2009 L’Aquila (Italy) earthquake. We show that the motion of the whole Adria microplate changed before the 2009 earthquake, and slowed down by around 20%. We demonstrate with quantitative models that the torque required upon Adria in order to drive such a kinematic change is consistent with what is imparted to Adria by temporal stress variations occurring during the late interseismic phase of the 2009 L’Aquila earthquake cycle. The inference that plate motions can be influenced by, and thus sensitive to, earthquake cycles offers an additional perspective to assessing the seismic potential of tectonic margins. Earth's outer shell is divided into a number of units—the tectonic plates—that move relative to each other at rates of few mm to cm per year. These relative motions are at the origin of the slow accumulation, along tectonic margins, of energy that is later released suddenly via earthquakes—a decade/century–long process generally referred to as earthquake cycle. It is commonly assumed that plate motions remain steady over such cycles. This is a central assumption in virtually all models of earthquake origin and seismic hazard. The ability to measure via geodetic techniques the contemporary motions of tectonic plates over periods of few years makes it possible to test the assumption above against observations. Here we focus on the Adria microplate, a tectonic unit comprising the Northern and Central parts of Italy, and accommodating the motion of Africa toward Eurasia. We show that the geodetically–observed motion of Adria slowed down during the years immediately preceding the MW6.3 earthquake that occurred on 6 April 2009 near the city of L’Aquila, Italy, which is located along the southwestern tectonic margin of Adria. We demonstrate that the force required to slow down the Adria motion is similar to that developing along the portion of crustal fault that later generated the 2009 L’Aquila earthquake. Adria microplate motion observed from Global Navigation Satellite Systems data slowed down by around 20% in the years preceding the 2009 L'Aquila earthquakeThe slowdown is larger than what permitted by data uncertainties or the impact of data noise, and is thus deemed tectonically meaningfulThe Adria motion slowdown requires a force upon Adria consistent with that imparted to Adria by the interseismic stress gain prior to 2009 Adria microplate motion observed from Global Navigation Satellite Systems data slowed down by around 20% in the years preceding the 2009 L'Aquila earthquake The slowdown is larger than what permitted by data uncertainties or the impact of data noise, and is thus deemed tectonically meaningful The Adria motion slowdown requires a force upon Adria consistent with that imparted to Adria by the interseismic stress gain prior to 2009
- Published
- 2024
- Full Text
- View/download PDF
157. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome
- Author
-
Disanto, G1, Adiutori, R2, Dobson, R2, Martinelli, V3, Dalla Costa G3, Runia, T4, Evdoshenko, E5, Thouvenot, E6, Trojano, M7, Norgren, N8, Teunissen, C9, Kappos, L10, Giovannoni, G2, Kuhle, J, Bianchi, L, Topping, J, Bestwick, Jp, Meier, Uc, Lazareva, N, Iaffaldano, P, Direnzo, V, Khademi, M, Piehl, F, Comabella, M, Sombekke, M, Killestein, J, Hegen, H, Rauch, S, D'Alfonso, S, Alvarez-Cermeño, Jc, Kleinová, P, Horáková, D, Roesler, R, Lauda, F, Llufriu, S, Avsar, T, Uygunoglu, U, Altintas, A, Saip, S, Menge, T, Rajda, C, Bergamaschi, R, Moll, N, Khalil, M, Marignier, R, Dujmovic, I, Larsson, H, Malmestrom, C, Scarpini, E, Fenoglio, C, Wergeland, S, Laroni, A, Annibali, V, Romano, S, Martínez, Ad, Carra, A, Salvetti, M, Uccelli, A, Torkildsen, Ø, Myhr, Km, Galimberti, D, Rejdak, K, Lycke, J, Frederiksen, Jl, Drulovic, J, Confavreux, C, Brassat, D, Enzinger, C, Fuchs, S, Bosca, I, Pelletier, J, Picard, C, Colombo, E, Franciotta, D, Derfuss, T, Lindberg, Rl, Yaldizli, Ö, Vécsei, L, Kieseier, Bc, Hartung, Hp, Villoslada, P, Siva, A, Saiz, A, Tumani, H, Havrdová, E, Villar, Lm, Leone, M, Barizzone, N, Deisenhammer, F, Montalban, X, Tintoré, M, Olsson, T, Lehmann, S, Castelnovo, G, Lapin, S, Hintzen, R, Furlan, R, Comi, G, Ramagopalan, Sv., Institut de Génomique Fonctionnelle (IGF), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Laboratory Medicine, Amsterdam Neuroscience - Neuroinfection & -inflammation, Disanto, G., Adiutori, R., Dobson, R., Martinelli, V., Dalla Costa, G., Runia, T., Evdoshenko, E., Thouvenot, E., Trojano, M., Norgren, N., Teunissen, C., Kappos, L., Giovannoni, G., Kuhle, J., on behalf of the International ClinicallyIsolated Syndrome Study, Group, and Neurology
- Subjects
Male ,Pathology ,Future studies ,Gastroenterology ,0302 clinical medicine ,Neurofilament Proteins ,Multiple Sclerosi ,0303 health sciences ,Clinically isolated syndrome ,medicine.diagnostic_test ,Medicine (all) ,Neurofilament Protein ,Demyelinating Disease ,Magnetic Resonance Imaging ,Psychiatry and Mental Health ,Predictive value of tests ,Disease Progression ,Biomarker (medicine) ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,Female ,Human ,Adult ,medicine.medical_specialty ,Multiple Sclerosis ,Neurofilament light ,multiple sclerosis ,adult ,axons ,biomarkers ,demyelinating diseases ,disease progression ,female ,follow-up studies ,humans ,magnetic resonance imaging ,male ,neurofilament proteins ,predictive value of tests ,neurology (clinical) ,psychiatry and mental health ,surgery ,arts and humanities (miscellaneous) ,medicine (all) ,[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery ,Axon ,Follow-Up Studie ,03 medical and health sciences ,Arts and Humanities (miscellaneous) ,Predictive Value of Tests ,Internal medicine ,medicine ,Humans ,In patient ,MULTIPLE SCLEROSIS ,030304 developmental biology ,business.industry ,Multiple sclerosis ,Magnetic resonance imaging ,Biomarker ,medicine.disease ,Axons ,[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health ,Surgery ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,Biomarkers ,Demyelinating Diseases ,Follow-Up Studies - Abstract
International audience; BACKGROUND:Neurofilament light chain (NfL) represents a promising biomarker for axonal injury. We present the first exploratory study on serum NfL in patients with a clinically isolated syndrome (CIS) and healthy controls.METHODS:We investigated serum NfL levels in 100 patients with CIS with a short conversion interval to clinically definite multiple sclerosis (MS) (fast converters (FC), median (IQR) conversion time: 110 days (79-139)); 98 patients with non-converting CIS (non-converters (NC), follow-up: 6.5 years (5.3-7.9)); and 92 healthy controls.RESULTS:NfL levels were higher in FC (24.1 pg/mL (13.5-51.8)) and NC (19.3 pg/mL (13.6-35.2)) than in healthy controls (7.9 pg/mL (5.6-17.2)) (OR=5.85; 95% CI 2.63 to 13.02; p = 1.5 × 10(-5) and OR = 7.03; 95% CI 2.85 to 17.34; p = 2.3 × 10(-5), respectively). When grouping FC and NC, increased serum NfL concentration was also associated with increasing numbers of T2 hyperintense MRI lesions (OR = 2.36; 95% CI 1.21 to 4.59; p = 0.011), gadolinium-enhancing lesions (OR = 2.69; 95% CI 1.13 to 6.41; p=0.026) and higher disability scores (OR = 2.54; 95% CI 1.21 to 5.31; p = 0.013) at CIS diagnosis.CONCLUSIONS:If replicated in future studies, serum NfL may represent a reliable and easily accessible biomarker of early axonal damage in CIS and MS.
- Published
- 2016
158. Detection of disability worsening in relapsing‐remitting multiple sclerosis patients: a real‐world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register.
- Author
-
Lepore, V., Bosetti, C., Santucci, C., Iaffaldano, P., Trojano, M., Mosconi, P., Totaro, Rocco, Coniglio, Maria Gabriella, Bossio, Roberto Bruno, Valentino, Paola, Gatto, Maurizia, Paolicelli, Damiano, Ardito, Bonaventura, Barcella, Valeria, Capone, Lorenzo, Nicolao, Piero, Lugaresi, Alessandra, Rini, Augusto, Bianchi, Marta, and Plasmati, Imma
- Subjects
MULTIPLE sclerosis ,DISABILITIES ,DISEASE relapse - Abstract
Background and purpose: In relapsing‐remitting multiple sclerosis patients (RRMS) disability progressively accumulates over time. To compare the cumulative probability of 6‐month confirmed disability‐worsening events using a fixed baseline or a roving Expanded Disability Status Scale (EDSS) reference, in a real‐world setting. Methods: A cohort of 7964 RRMS patients followed for 2 or more years, with EDSS scores recorded every 6 months, was selected from the Italian Multiple Sclerosis Register. The overall probability of confirmed disability‐worsening events and of confirmed disability‐worsening events unrelated to relapse was evaluated using as reference a fixed baseline EDSS score or a roving EDSS score in which the increase had to be separated from the last EDSS assessment by at least 6 or 12 months. Results: Using a fixed baseline EDSS reference, the cumulative probability of 6‐year overall confirmed disability‐worsening events was 33.2%, and that of events unrelated to relapse was 10.9% (33% of overall confirmed disability‐worsening events). Using a roving EDSS, the proportions were respectively 35.2% and 21.3% (61% of overall confirmed disability‐worsening events). Conclusions: In a real‐world setting, roving EDSS reference scores appear to be more sensitive for detecting confirmed disability‐worsening events unrelated to relapse in RRMS patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
159. Hyperthermic intrathoracic chemotherapy combined to iterative cytoreductive surgery to treat a pleural carcinosis from psudomixoma peritonei. A case report.
- Author
-
LOCOCO, F., DI GIORGIO, A., IAFFALDANO, A., SCHINZARI, G., TABACCO, D., ACETO, P., ABATINI, C., SOLLAZZI, L., and MARGARITORA, S.
- Abstract
Pseudomyxoma peritonei (PMP) is an uncommon disease with locally-invasive attitude. Intrathoracic spread is rarely reported and its management extremely challenging. A 51-year-old Caucasian female presented with left pleural carcinosis 9-months after two sequential abdominal surgical procedures combined with HIPEC for low-grade PMP. Cytoreductive surgery (pleurectomy/decortication) was followed by 60-minutes hyperthermic intrathoracic chemotherapy mitomycin-C (215 mg/m2) infusing at same temperature (42°C) and intrapleural pression (2-4 mmH2O). No intra-operative complication occurred, the post-op stay was uneventful and no sign of recurrence was observed 9-months after surgery. Cytoreductive thoracic surgery and hyperthermic chemotherapy (HITHOC) could be a feasible therapeutic option in very selected cases. [ABSTRACT FROM AUTHOR]
- Published
- 2021
160. Postmarketing evidence of disease-modifying drugs in multiple sclerosis
- Author
-
Trojano, Maria, Paolicelli, Damiano, Fuiani, Aurora, Pellegrini, Fabio, Iaffaldano, Pietro, Direnzo, Vita, and D’Onghia, Mariangela
- Published
- 2008
- Full Text
- View/download PDF
161. Epstein-Barr-negative MS: a true phenomenon?
- Author
-
Dobson, Ruth, Kuhle, Jens, Middeldorp, Jaap, Giovannoni, Gavin, on behalf of the international CIS study investigators including Dalla Costa, G, Furlan, R, Martinelli, V, Comi, G, Runia, T, Hintzen, R, Evdoshenko, E, Lazareva, N, Lapin, S, Thouvenot, E, Lehmann, S, Castelnovo, G, Iaffaldano, P, Direnzo, V, Trojano, M, Khademi, . M, Piehl, F, Olsson, T, Comabella, M, Montalban, X, Tintoré, M, Sombekke, M, Killestein, J, Teunissen, C, Hegen, H, Deisenhammer, F, Rauch, S, D'Alfonso, S, Barizzone, N, Alvarez Cermeño, Jc, Villar, Lm, Kleinová, P, Horáková, D, Havrdová, E, Roesler, R, Lauda, F, Tumani, H, Llufriu, S, Villoslada, P, Saiz, A, Avsar, T, Uygunoglu, U, Altintas, A, Saip, S, Siva, A, Menge, T, Kieseier, Bc, Hartung, Hp, Rajda, C, Vécsei, L, Bergamaschi, R, Colombo, E, Franciotta, D, Moll, N, Pelletier, J, Picard, C, Khalil, M, Enzinger, C, Fuchs, S, Marignier, R, Confavreux, C, Dujmovic, I, Drulovic, J, Larsson, H, Malmestrom, C, Lycke, J, Scarpini, E, C. Fenoglio, C, Galimberti, D, Wergeland, S, Torkildsen, Ø, Myhr, Km, Laroni, Alice, Uccelli, Antonio, Annibali, V, Romano, S, Salvetti, M, Martínez, Ad, Carra, A, Rejdak, K, Frederiksen, Jl, Brassat, D, Bosca, I, Casanova, B, Derfuss, T, Lindberg, R, Yaldizli, Ö, Kappos, L, Leone, M., and Pathology
- Subjects
0301 basic medicine ,business.industry ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Neurology ,Epstein barr ,Phenomenon ,Medicine ,Neurology (clinical) ,business ,Competence (human resources) ,Social psychology ,Clinical/Scientific Notes ,030217 neurology & neurosurgery - Abstract
This work was supported by institutional funding and in part by the BMBF grant KKNMS (Competence Net Multiple Sclerosis) to H Tumani.
- Published
- 2017
162. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis
- Author
-
Baroncini, Damiano, Simone, Marta, Iaffaldano, Pietro, Brescia Morra, Vincenzo, Lanzillo, Roberta, Filippi, Massimo, Romeo, Marzia, Patti, Francesco, Chisari, Clara Grazia, Cocco, Eleonora, Fenu, Giuseppe, Salemi, Giuseppe, Ragonese, Paolo, Inglese, Matilde, Cellerino, Maria, Margari, Lucia, Comi, Giancarlo, Zaffaroni, Mauro, and Ghezzi, Angelo
- Abstract
IMPORTANCE: Availability of new disease-modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear whether this improvement also involves patients with pediatric-onset MS (POMS), whose early management is more challenging. OBJECTIVE: To evaluate changes in the prognosis of POMS over time in association with changes in therapeutic and managing standards. DESIGN, SETTING, AND PARTICIPANTS: Retrospective, multicenter, observational study. Data were extracted and collected in May 2019 from the Italian MS Registry, a digital database including more than 59 000 patients. Inclusion criteria were MS onset before age 18 years, diagnosis before January 2014, and disease duration of at least 3 years. Exclusion criteria were primary progressive MS, Expanded Disability Status Scale (EDSS) score of at least 8 one year after onset, unavailability of diagnosis date, and less than 2 EDSS score evaluations. Eligible patients were 4704 patients with POMS. According to these criteria, we enrolled 3198 patients, excluding 1506. EXPOSURES: We compared time to reach disability milestones by epoch of MS diagnosis (<1993, 1993-1999, 2000-2006, and 2007-2013), adjusting for possible confounders linked to EDSS evaluations and clinical disease activity. We then analyzed the difference among the 4 diagnosis epochs regarding demographic characteristics, clinical disease activity at onset, and DMTs management. MAIN OUTCOMES AND MEASURES: Disability milestones were EDSS score 4.0 and 6.0, confirmed in the following clinical evaluation and in the last available visit. RESULTS: We enrolled 3198 patients with POMS (mean age at onset, 15.2 years; 69% female; median time to diagnosis, 3.2 years; annualized relapse rate in first 1 and 3 years, 1.3 and 0.6, respectively), with a mean (SD) follow-up of 21.8 (11.7) years. Median survival times to reach EDSS score of 4.0 and 6.0 were 31.7 and 40.5 years. The cumulative risk of reaching disability milestones gradually decreased over time, both for EDSS score of 4.0 (hazard ratio [HR], 0.70; 95% CI, 0.58-0.83 in 1993-1999; HR, 0.48; 95% CI, 0.38-0.60 in 2000-2006; and HR, 0.44; 95% CI, 0.32-0.59 in 2007-2013) and 6.0 (HR, 0.72; 95% CI, 0.57-0.90; HR, 0.44; 95% CI, 0.33-0.60; and HR, 0.30; 0.20-0.46). In later diagnosis epochs, a greater number of patients with POMS were treated with DMTs, especially high-potency drugs, that were given earlier and for a longer period. Demographic characteristics and clinical disease activity at onset did not change significantly over time. CONCLUSIONS AND RELEVANCE: In POMS, the risk of persistent disability has been reduced by 50% to 70% in recent diagnosis epochs, probably owing to improvement in therapeutic and managing standards.
- Published
- 2021
- Full Text
- View/download PDF
163. Life History Antecedents of Vocational Indecision.
- Author
-
Iaffaldano, Michelle
- Abstract
Assessed the validity of using systematic life history information to predict three vocational decision-making criteria in 200 college students: vocational decidedness and its two components, vocational identity and vocational maturity. Significant typologies were identified, however, results indicated that the overall construct of vocational decidedness differs somewhat for males and females. (Author/BL)
- Published
- 1985
164. Long-Term, Comparative Safety Study of People with Multiple Sclerosis Newly Started on Cladribine Tablets (CLARION): Study Status Update and Representativeness.
- Author
-
Ziemssen, Tjalf, Wergeland, Stig, Butzkueven, Helmut, Magyari, Melinda, Hillert, Jan, Soilu-Hänninen, Merja, Trojano, Maria, Iaffaldano, Pietro, Kuhle, Jens, Moore, Nicholas, Mushnikov, Vasili, Bezemer, Irene, and Sabidó, Meritxell
- Abstract
Cladribine tablets (CladT) is an established disease-modifying therapy for multiple sclerosis (MS), with an estimated cumulative exposure of 65,000 people/126,000 person-years since launch (to December 2022). The CLARION study aimed to enroll 8000 participants (4000 in the CladT and fingolimod cohorts) and relied on secondary use of data from pre-existing MS registries/data sources (except in Germany, where primary data collection is performed). Participant counts were obtained periodically and by August 2023 included 10 participating MS registries/data sources across 17 countries. Participant characteristics and representativeness were assessed from 8 MS registries/data sources (cut off September 2022 – August 2023). By August 2023, 9555 people with MS were included in CLARION from the 10 participating MS registries/data sources (n=5266 and n=4289, respectively, in the CladT and fingolimod cohorts). Participants were included mostly from the Italian MS Registry (34.2%), MSBase (multiple countries; 17.5%), Norwegian MS Registry and Biobank (11.4%), and the MS Documentation System 3D (MSDS3D, Germany; 10.1%). The majority of participants were female and the average age at MS onset and diagnosis was in the early thirties. Over 90% of people included in CLARION have a confirmed diagnosis of relapsing-remitting MS. Representativeness of the MS population is adequately addressed by the participation of several countries in the European region and countries with different prevalence of MS and incidence rate of malignancies and infections, in particular tuberculosis. The study size was successfully reached in both cohorts, allowing for the CLARION study to generate meaningful real-world evidence concerning the safety profile of CladT during follow-up over the coming decade, in a representative MS population. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
165. Italian semen cryobank of autochthonous chicken and turkey breeds: a tool for preserving genetic biodiversity
- Author
-
Iaffaldano, Nicolaia, Di Iorio, Michele, Rusco, Giusy, Antenucci, Emanuele, Zaniboni, Luisa, Madeddu, Manuela, Marelli, Stefano, Schiavone, Achille, Soglia, Dominga, Buccioni, Arianna, Cassandro, Martino, Castellini, Cesare, Marzoni, Margherita, and Cerolini, Silvia
- Abstract
AbstractThe creation of genetic resource cryobanks provides a crucial link between in situand ex situtechniques to improve the efficiency of conservation programs. Aim of the present review is to describe all the activities developed for the implementation of the first Italian Semen Cryobank of Autochthonous Chicken and Turkey Breeds. These activities can be classified into three main topics: (1) identification of species-specific semen freezing/thawing reference procedures; (2) drafting Standard Operative Procedures (SOP) for the implementation of the semen cryobank; (3) storage of semen doses from Italian chicken and turkey breeds to establish the cryobank. Several trials have been developed to identify a specie-specific semen cryopreservation protocol for chickens and turkeys. The major results are reviewed and a final reference protocol described. Taking into consideration the FAO guidelines for cryoconservation of animal genetic resources, SOP were drafted with the aim to provide technical guidance and logistical support on the choice of priority breeds, selection of birds for semen production, infrastructures and storage sites, birds and semen management, cryopreservation process and doses traceability. Lastly, the Italian Semen Cryobank was created. A total of 112 semen doses from 22 cockerels of three breeds, and 74 doses from 12 turkey males of three breeds were stored in the Cryobank. Breed specific semen quality parameters assessed before and after cryopreservation are reported. The described activities provide information and tools useful for the implementation of semen cryobanking in avian species and might be transferred also to other species after appropriate adaptations.HIGHLIGHTSImplementation of the first Italian Semen Cryobank of Autochthonous Chicken and Turkey BreedsDrafting Standard Operative Procedures provides technical guidance and logistical support on the design and establishment of the cryobankSemen cryobank is a precious genetic reservoir and could be useful to safeguard genetic variability in small population in vivoconserved
- Published
- 2021
- Full Text
- View/download PDF
166. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone
- Author
-
Martinelli, V., Cocco, E., Capra, R., Salemi, G., Gallo, P., Capobianco, M., Pesci, I., Ghezzi, A., Pozzilli, Carlo, Lugaresi, A., Bellantonio, P., Amato, M. P., Grimaldi, L. M., Trojano, M., Mancardi, G. L., Bergamaschi, R., Gasperini, Claudio, Rodegher, M., Straffi, L., Ponzio, M., Comi, G., For The Italian Mitoxantrone Group, Radaelli, M, Esposito, F, Moiola, L, Colombo, B, Rossi, P, Marrosu, Mg, Frau, J, Lorefice, L, Coghe, G, Savettieri, Giovanni, Ragonese, P, Cusimano, V, Perini, P, Rinaldi, F, Vidali, A, Bertolotto, A, Malucchi, S, Di Sapio, A, Montanari, E, Guareschi, A, Rizzo, A, Zaffaroni, M, Baldini, S, De Rossi, N, Cordioli, C, Rasia, S, Salvetti, M, Buttinelli, C, AUSILI CEFARO, Luca, De Luca, G, Tommaso, D, Farina, D, Fantozzi, R, Ruggieri, S, Amato, Mp, Hakiki, B, Zipoli, V, Portaccio, E, Bartolozzi, Ml, Scandellari, C, Stecchi, S, Marchello, Lp, Palmeri, B, Vitello, G, Iaffaldano, P, Lucchese, G, Dattola, V, Buccafusca, M, Sola, P, Simone, Am, Barreca, F, Patti, F, Laisa, P, Cavalla, P, Masera, S, Tavazzi, E, Galgani, S, Tedeschi, G, Sacco, R, Provinciali, L, Maura, D, Lus, G, Alfieri, G, Ticca, A, Piras, Ml, Maimone, D, Bianca, M, Iudice, A, Giro, Me, Galeotti, M, Florio, C, Spitalieri, P, La Mantia, L, Motti, L, Rottoli, Mr, Granella, F, Solaro, C, Scarpini, E, Servillo, G, Cavaletti, G., Martinelli, V., Cocco, E., Capra, R., Salemi, G., Gallo, P., Capobianco, M., Pesci, I., Ghezzi, A., Pozzilli, C., Lugaresi, A., Bellantonio, P., Amato, M. P., Grimaldi, L. M., Trojano, M., Mancardi, G. L., Bergamaschi, R., Gasperini, C., Rodegher, M., Straffi, L., Ponzio, M., Comi, G., Radaelli, M., Esposito, F., Moiola, L., Colombo, B., Rossi, P., Marrosu, M. G., Frau, J., Lorefice, L., Coghe, G., Savettieri, G., Ragonese, P., Cusimano, V., Perini, P., Rinaldi, F., Vidali, A., Bertolotto, A., Malucchi, S., Di Sapio, A., Montanari, E., Guareschi, A., Rizzo, A., Zaffaroni, M., Baldini, S., De Rossi, N., Cordioli, C., Rasia, S., Salvetti, M., Buttinelli, C., Ausili Cefaro, L., De Luca, Giovanna, Tommaso, D., Farina, D., Fantozzi, R., Ruggieri, S., Hakiki, B., Zipoli, V., Portaccio, E., Bartolozzi, M. L., Scandellari, C., Stecchi, S., Marchello, L. P., Palmeri, B., Vitello, G., Iaffaldano, P., Lucchese, G., Dattola, V., Buccafusca, M., Sola, P., Simone, A. M., Barreca, F., Patti, F., Laisa, P., Cavalla, P., Masera, S., Tavazzi, E., Galgani, S., Tedeschi, G., Sacco, R., Provinciali, L., Maura, D., Lus, G., Alfieri, G., Ticca, A., Piras, M. L., Maimone, D., Bianca, M., Iudice, A., Giro, M. E., Galeotti, M., Florio, C., Spitalieri, P., La Mantia, L., Motti, L., Rottoli, M. R., Granella, F., Solaro, C., Scarpini, E., Servillo, G., Cavaletti, G., Radaelli, M, Esposito, F, Moiola, L, Colombo, B, Rossi, P, Marrosu, MG, Frau, J, Lorefice, L, Coghe, G, Savettieri, G, Ragonese, P, Cusimano, V, Perini, P, Rinaldi, F, Vidali, A, Bertolotto, A, Malucchi, S, Di Sapio, A, Montanari, E, Guareschi, A, Rizzo, A, Zaffaroni, M, Baldini, S, De Rossi, N, Cordioli, C, Rasia, S, Salvetti, M, Buttinelli, C, Ausili Cefaro, L, De Luca, G, Tommaso, D, Farina, D, Fantozzi, R, Ruggieri, S, Amato, MP, Hakiki, B, Zipoli, V, Portaccio, E, Bartolozzi, ML, Scandellari, C, Stecchi, S, Marchello, LP, Palmeri, B, Vitello, G, Iaffaldano, P, Lucchese G, Dattola V, Buccafusca M, Sola, P, Simone, AM, Barreca, F, Patti, F, Laisa, P, Cavalla, P, Masera, S, Tavazzi, E, Galgani, S, Tedeschi, G, Sacco, R, Provinciali, L, Maura, D, Lus, G, Alfieri, G, Ticca, A, Piras, ML, Maimone, D, Bianca, M, Iudice, A, Giro, ME, Galeotti, M, Florio, C, Spitalieri, P, La Mantia, L, Motti, L, Rottoli, MR, Granella, F, Solaro, C, Scarpini, E, Servillo, G, Cavalletti, G, Salemi, G, Martinelli, V, Cocco, E, Capra, R, Gallo, P, Capobianco, M, Pesci, I, Ghezzi, A, Pozzilli, C, Lugaresi, A, Bellantonio, P, Amato, M, Grimaldi, L, Trojano, M, Mancardi, G, Bergamaschi, R, Gasperini, C, Rodegher, M, Straffi, L, Ponzio, M, Comi, G, Cavaletti, G, and DIPARTIMENTO DI SCIENZE BIOMEDICHE E NEUROMOTORIE
- Subjects
Male ,medicine.medical_specialty ,Myeloid ,mitoxantrone ,acute myelocytic leukemia ,multiple sclerosis ,Population ,Statistics, Nonparametric ,Follow-Up Studie ,Arts and Humanities (miscellaneous) ,Retrospective Studie ,Internal medicine ,Multiple Sclerosi ,medicine ,Humans ,multiple sclerosis, leukemia, mitoxantrone ,Prospective cohort study ,education ,Retrospective Studies ,Aged ,Analgesics ,education.field_of_study ,Mitoxantrone ,Cumulative dose ,business.industry ,Multiple sclerosis ,Incidence (epidemiology) ,leukemia ,Myeloid leukemia ,Retrospective cohort study ,medicine.disease ,Confidence interval ,Surgery ,Leukemia ,Leukemia, Myeloid, Acute ,medicine.anatomical_structure ,Italy ,Cohort ,Settore MED/26 - Neurologia ,Analgesic ,Female ,Neurology (clinical) ,business ,Follow-Up Studies ,medicine.drug ,Human - Abstract
none 25 no Abstract OBJECTIVES: To evaluate the incidence and dose-dependency of mitoxantrone (MTX)-associated acute myelocytic leukemia (AML) in the network of Italian multiple sclerosis (MS) clinics. METHODS: We performed a multicenter retrospective cohort study of patients treated with MTX in MS centers under the Italian national health care system between 1998 and 2008. Demographic, disease, treatment, and follow-up information were collected using hospital records. RESULTS: Data were available for 3,220 patients (63% women) from 40 Italian centers. Follow-up (mean ± SD) was 49 ± 29 months (range 12-140 months). We observed 30 cases of AML (incidence 0.93% [95% confidence interval 0.60%-1.26%]). The mean cumulative dose was higher in patients with AML (78 vs 65 mg/m(2), p = 0.028). The median interval from the start of therapy to AML diagnosis was longer than expected at 33 months (range 13-84 months); 8 patients (27%) developed AML 4 years or more after the first MTX infusion. The rate of mortality associated with AML was 37%. CONCLUSIONS: This higher than expected risk of AML and related mortality requires that treatment decisions must be made jointly between clinicians and patients who understand their prognosis, treatment options, and treatment-related risks. The now large exposed MS population must be monitored for hematologic abnormalities for at least 6 years from the end of therapy, to ensure the rapid actions needed for early diagnosis and treatment of AML. none Martinelli V; Cocco E; Capra R; Salemi G; Gallo P; Capobianco M; Pesci I; Ghezzi A; Pozzilli C; Lugaresi A; Bellantonio P; Amato MP; Grimaldi LM; Trojano M; Mancardi GL; Bergamaschi R; Gasperini C; Rodegher M; Straffi L; Ponzio M; Comi G; For The Italian Mitoxantrone Group; De Luca G; Di Tommaso V; Farina D Martinelli V; Cocco E; Capra R; Salemi G; Gallo P; Capobianco M; Pesci I; Ghezzi A; Pozzilli C; Lugaresi A; Bellantonio P; Amato MP; Grimaldi LM; Trojano M; Mancardi GL; Bergamaschi R; Gasperini C; Rodegher M; Straffi L; Ponzio M; Comi G; For The Italian Mitoxantrone Group; De Luca G; Di Tommaso V; Farina D
- Published
- 2011
167. Predictors of definite Multiple Sclerosis in patients with pediatric onset first demyelinating clinical attack
- Author
-
SALEMI, Giuseppe, Iaffaldano P, Lucisano G, Ghezzi A, Comi V, Brescia Morra V, Patti F, Lugaresi A, Pozzilli C, Amato M, Millefiorini E, Lus G, Zimatore G, Maimone D, Coniglio G, Bergamaschi R, Marrosu M, Tedeschi G, Ardito D, Giuliani G, Avolio C, Montanari E, Simone M, Margari L, Lepore V, Trojano M., Salemi, G, and Iaffaldano P, Lucisano G, Ghezzi A, Comi V, Brescia Morra V, Patti F, Lugaresi A, Pozzilli C, Amato M, Millefiorini E, Lus G, Zimatore G, Maimone D, Coniglio G, Bergamaschi R, Marrosu M, Tedeschi G, Ardito D, Giuliani G, Avolio C, Montanari E, Simone M, Margari L, Lepore V, Trojano M
- Subjects
Multiple Sclerosis, pediatric onset ,Settore MED/26 - Neurologia - Published
- 2014
168. Comorbidities affect treatment choice and persistence in RRMS: a real-life multicenter study
- Author
-
Laroni, A., Signori, A., Maniscalco, G., Lanzillo, Raffaella, Sacca', Filippo, Clerico, Marinella, Lo Fermo, S., Annovazzi, P., Bonavita, S., Baroncini, D., Rasia, S., Cordioli, C., Prosperni, L., Cocco, Eleonora, Torri Clerici, V., Sartori, A., Signoriello, E., Repice, A., Zarbo, I., Cerqua, R., Pontecorvo, S., Di Sapio, A., Lavorgna, L., Barillà, C., La Gioia, S., Frigeni, B., Iaffaldano, P., Binello, Eleonora, Russo, Valentina, Esposito, S., Frau, J., Gallo, F., and Sorman, M.
- Published
- 2016
169. To switch therapies in RRMS: why and when? A real-life multicentre study
- Author
-
Marinella CLERICO, Signori, A., Maniscalco, G. T., Sacca, F., Lanzillo, R., Lo Fermo, S., Annovazzi, P., Prosperini, L., Cocco, E., Bonavita, S., Clerici, V. Torri, Laroni, A., Repice, A., Zarbo, I. R., Cerqua, R., Di Sapio, A., Pontecorvo, S., Lavorgna, L., Barilla, C., Cordioli, C., Sartori, A., Signoriello, E., La Gioia, S., Frigeni, B., Iaffaldano, P., Di Liberto, A., Frau, J., Gallo, F., and Sormani, M. P.
- Published
- 2016
170. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment
- Author
-
Trojano, M, Pellegrini, F, Paolicelli, D, Fuiani, A, Zimatore, Gb, Tortorella, C, Simone, Il, Patti, F, Ghezzi, A, Portaccio, E, Rossi, P, Pozzilli, C, Salemi, G, Lugaresi, A, Bergamaschi, R, Millefiorini, E, Clerico, Marinella, Lus, G, Vianello, M, Avolio, C, Cavalla, P, Iaffaldano, P, Direnzo, V, D'Onghia, M, Lepore, V, Livrea, P, Comi, G, Amato, Mp, Italian Multiple Sclerosis Database Network Group, Trojano, M., Pellegrini, F., Paolicelli, D., Fuiani, A., Zimatore, G., Tortorella, C., Simone, I., Patti, F., Ghezzi, A., Portaccio, E., Rossi, P., Pozzilli, C., Salemi, G., Lugaresi, A., Bergamaschi, R., Millefiorini, E., Clerico, M., Lus, Giacomo, Vianello, M., Avolio, C., Cavalla, P., Iaffaldano, P., Direnzo, V., D'Onghia, M., Lepore, V., Livrea, P., Comi, G., Amato, M., ITALIAN MULTIPLE SCLEROSIS DATABASE NETWORK, . ., Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Portaccio E, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Iaffaldano P, Direnzo V, D'Onghia M, Lepore V, Livrea P, Comi G, Amato MP, M Trojano, F Pellegrini, D Paolicelli, A Fuiani, GB Zimatore, C Tortorella C, IL Simone, F Patti, A Ghezzi, E Portaccio, P Rossi, C Pozzilli, G Salemi, A Lugaresi, and on behalf of Italian Multiple Sclerosis Database Network (MSDN) group
- Subjects
Adult ,Male ,medicine.medical_specialty ,Multiple Sclerosis ,Propensity score ,Disease ,gender ,interferon beta ,multiple sclerosis ,observational study ,propensity score ,Lower risk ,Severity of Illness Index ,Multiple sclerosis, Interferon beta, Gender, Observational study, Propensity score ,Cohort Studies ,Disability Evaluation ,Young Adult ,Sex Factors ,gender, multiple sclerosis, treatment, interferon ,Double-Blind Method ,Internal medicine ,Observational study ,medicine ,Confidence Intervals ,Odds Ratio ,Product Surveillance, Postmarketing ,Humans ,Immunologic Factors ,Multiple sclerosi ,Proportional Hazards Models ,Expanded Disability Status Scale ,Proportional hazards model ,business.industry ,Multiple sclerosis ,Drug Administration Routes ,Interferon-beta ,medicine.disease ,Interferon beta ,Surgery ,Neurology ,Italy ,Cohort ,Propensity score matching ,Regression Analysis ,Settore MED/26 - Neurologia ,Female ,Neurology (clinical) ,business - Abstract
Background: There are a few and conflicting results from randomised controlled trials (RCTs) pertaining to the influence of gender in response to currently used disease modifying drugs in Multiple Sclerosis (MS). Observational studies may be especially valuable for answering effectiveness questions in subgroups not studied in RCTs. Objective: To conduct a post-marketing analysis aimed to evaluate the gender effect on Interferon beta (IFN beta) treatment response in a cohort of relapsing (RR) MS patients. Methods: A cohort of 2570 IFN beta-treated RRMS was prospectively followed for Lip to 7 years in 15 Italian MS Centers. Cox proportional hazards regression models were used to assess gender differences for risk of reaching 1st relapse and risk of progression by I point on Expanded Disability Status Scale (EDSS) score. Gender effects were also explored by a propensity score (PS) matching algorithm, and a tree-growing technique. Results: The multivariate Cox Regression analyses showed that male patients had a significant (p = 0.0097) lower risk for 1st relapse and a trend (p = 0.0897) for a higher risk to reach I point EDSS progression than females. The PS matched multivariate Cox Regression confirmed these results. The RECPAM analysis showed that male sex conferred a significant reduction in the risk for 1st relapse (HR = 0.86; 95% Cl = 0.76-0.98; p = 0.0226) in the subgroup with a low pre-treatment number of bouts, and a significant increase in the risk for I point EDSS progression (HR = 1.33; 95% Cl: 1.00-1.76; p
- Published
- 2009
171. Improving the Rabbit Semen Cryopreservation Protocol: Comparison Between Two Extenders and Inseminating Doses
- Author
-
Di Iorio, Michele, Rusco, Giusy, Colonna, Maria Antonietta, Schiavitto, Michele, D’Andrea, Maria Silvia, Cerolini, Silvia, and Iaffaldano, Nicolaia
- Abstract
This study has been designed to optimize the semen freezing protocol in rabbits, in this regard we compared a Tris-citrate-glucose (TCG) extender with a commercial one (Cortalap®), that to the best of our knowledge has never been used up to now on the in vitrofreezability and fertilizing ability of cryopreserved rabbit semen. Two different inseminating semen doses were considered. Five pooled semen samples were divided into two subsamples and each of them were diluted to a ratio 1:1 (v:v) with a freezing extender composed of TCG or Cortalap®containing 16% of dimethylsulfoxide and 0.1 mol/L of sucrose. The extended semen was filled into 0.25 mL plastic straws and frozen above a liquid nitrogen surface. After thawing (50°C/10 seconds) we determined sperm motility, viability, membrane functionality, acrosome and DNA integrity. Our results showed that the Cortalap®extender significantly improved the in vitropost-thaw sperm quality, in comparison to TCG. When we compared the extenders in vivo, no significant differences in the reproductive performances were observed independently by inseminating doses used. In this study we demonstrated that Cortalap®extender can be used as an alternative to TCG. Thus, the Cortalap®being a ready to use extender, implies a reduction of time, mistakes and microbial contaminations during its preparation. This discovery results as significant because it provides beyond an important contribution to the creation of the first Italian semen cryobank of rabbit breeds and also for livestock rabbit farms based on artificial insemination (AI) program.
- Published
- 2020
- Full Text
- View/download PDF
172. Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis
- Author
-
Chisari, Clara Grazia, Grimaldi, Luigi Maria, Salemi, Giuseppe, Ragonese, Paolo, Iaffaldano, Pietro, Bonavita, Simona, Sparaco, Maddalena, Rovaris, Marco, D'Arma, Alessia, Lugaresi, Alessandra, Ferrò, Maria Teresa, Grossi, Paola, Di Sapio, Alessia, Cocco, Eleonora, Granella, Franco, Curti, Erica, Lepore, Vito, Trojano, Maria, and Patti, Francesco
- Abstract
IntroductionNatalizumab (NTZ) is one of the most effective treatment options for multiple sclerosis (MS) treatment. Our study aimed to evaluate the effectiveness of NTZ when administered according to the extended dosing strategy compared with standard 4-weekly administration in a large Italian MS population.Materials and methodsThis retrospective multicentre study included patients with relapsing-remitting MS (RR-MS) who received NTZ administrations between the 1 June 2012 and the 15 May 2018 and were followed by the ‘Italian MS Register’. All patients with MS were stratified into two groups based on NTZ administration schedule: standard interval dosing (SID) patients who received infusions on average from 28 to 32 days (median 30) and extended interval dosing (EID) including patients who have been infused with interval between 33 and 49 days (median 43). Clinical data were assessed at baseline (before starting NTZ), after 12 (T1) and 24 months (T2) of treatment.ResultsOut of 5231 patients with RR-MS screened, 2092 (mean age 43.2±12.0, 60.6% women) were enrolled. A total of 1254 (59.9%) received NTZ according to SID, and 838 (40.1%) according to EID. At 12 and 24 months, no differences in terms of annualised relapse rate and disability status were found between the two groups. Progression index and confirmed disability worsening were similar between the two groups.DiscussionThe use of NTZ with an extended interval schedule showed similar effectiveness compared with SID. Unchanged clinical efficacy of EID schedule may raise the question of a possible advantage in terms of tolerability and safety.
- Published
- 2020
- Full Text
- View/download PDF
173. Free-Range Rearing Density for Male and Female Milanino Chickens: Growth Performance and Stress Markers
- Author
-
Mosca, Fabio, Zaniboni, Luisa, Iaffaldano, Nicolaia, Abdel Sayed, Ahmad, Mangiagalli, Maria G., Pastorelli, Grazia, and Cerolini, Silvia
- Abstract
The Milanino is a heavy Italian chicken breed and represents an important genetic resource for alternative production systems. Due to the absence of standard management guidelines for local chicken breeds, this study aims to determine the space requirement to achieve a good equilibrium between growth performance and stress response in Milanino chickens reared according to a separate-sex free-range program. A total of 140 birds (70M:70F) were reared in outdoor pens from 75 to 235 d of life according to the following experimental groups (35 birds/group): (M2) males in 2 m2/bird; (F2) females in 2 m2/bird; (M10) males in 10 m2/bird; (F10) females in 10 m2/bird. Growth performance and stress condition were recorded. Bird density affected male body weight, that was higher at the lower density of 10 m2/bird. In contrast, females showed a consistent growth rate irrespective of the bird density suggesting lower space requirements. An overall good adaptability of the breed to the separate-sex free-range system was found, irrespective of both sex and bird density. Moreover, the stress markers values assessed at the end of the growing period suggest the ability of Milanino birds to respond well to environmental stressors. The results provided in this report will be implemented into free-range management guidelines for meat production in the Milanino breed: the separate-sex rearing is recommended during the growing period in outdoor pens and the bird density has to be planned according to the sex.
- Published
- 2019
- Full Text
- View/download PDF
174. Free-range rearing density for male and female Milanino chickens: carcass yield and qualitative meat traits
- Author
-
Cerolini, Silvia, Vasconi, Mauro, Abdel Sayed, Ahmad, Iaffaldano, Nicolaia, Mangiagalli, Maria G., Pastorelli, Grazia, Moretti, Vittorio M., Zaniboni, Luisa, and Mosca, Fabio
- Abstract
The Milanino is a heavy Italian chicken breed and represents an important genetic resource for alternative production systems. In order to support its promotion in the market according to consumer expectations on healthy nutrition and animal welfare, this trial aims to study the slaughter performance and the meat quality in male and female Milanino chickens kept at different rearing density in a separate-sex free-range system. A total of 140 birds (70M:70F) were reared in outdoor pens from 75 to 235 d of life according to the following experimental groups (35 birds/group): M2) males in 2 m2/bird; F2) females in 2 m2/bird; M10) males in 10 m2/bird; F10) females in 10 m2/bird. At 235 d of age, 6 birds per group were slaughtered. Slaughter performance and meat quality were assessed. The Milanino chicken is characterized by high carcass weight and carcass yield among local chicken breeds, and a rearing density of 10 m2/bird is recommended for male birds to obtain heavier carcasses. Milanino meat appears bright and intensely colored, and it is characterized by high protein and low fat contents compared with the standard broiler meat. Total lipids of Milanino meat are characterized by a healthy fatty acid composition, corresponding to a high PUFA/SFA ratio. Milanino breast meat is a good supply of nutraceutical PUFA with a positive low n-6/n-3 PUFA ratio. The ability of the Milanino breed either to synthesize or to transfer to tissue a high quantity of PUFA relevant for human health could be a key factor for its economic valorization.
- Published
- 2019
- Full Text
- View/download PDF
175. Using Rigid Microplate Motions to Detect the Stress Buildup Preceding Large Earthquakes: A Feasibility Test Based on Synthetic Models
- Author
-
Martin de Blas, Juan and Iaffaldano, Giampiero
- Abstract
Assessing the temporal evolution of stresses along seismogenic faults is typically done by combining geodetic observations collected near the locations of previous large earthquakes with modeling of the interseismic, coseismic, and postseismic deformation. Here we explore whether it is feasible to link the charge phase of large earthquakes to rigid microplate motions, which can be inferred from geodetic observations that are instead collected further away from crustal faults. We use numerical simulations of the dynamics and associated kinematics of an idealized, rigid microplate subject to stress buildups and drop‐offs from a series of earthquakes. Simulations span the charging cycle of a single 6.5
- Published
- 2019
- Full Text
- View/download PDF
176. Influence of physicians' risk perception on switching treatments between high- efficacy and non–high-efficacy disease‑modifying therapies in multiple sclerosis.
- Author
-
Seifer, Gustavo, Arun, Tarunya, Capela, Carlos, Laureys, Guy, Jones, Eddie, Dominguez-Castro, Patricia, Sanchez-de la Rosa, Rainel, Hiltl, Simone, and Iaffaldano, Pietro
- Abstract
• Decision of treatment initiation for MS is influenced by several factors. • Physicians' risk perception was not a leading factor for treatment switch. • Most cited reason for treatment switch is lack of efficacy. • Treatment initiation with high efficacy DMTs as a first line can be considered. The decision of initiating treatment for multiple sclerosis (MS) with a high-efficacy DMT (HE DMT) or non–high-efficacy DMT (non-HE DMT) is influenced by several factors, including risk perception of patients and physicians. Investigate the influence of physicians' risk perception on decision-making when switching treatments for MS and the reasons for switching. Data were drawn from the Adelphi Real-World MS Disease-Specific Program (a retrospective survey) and analysis included people with RMS identified between 2017– 2021. Of 4129 patients with reasons for switch available, 3538 switched from non-HE DMT and 591 from HE DMT. Overall, 4.7% of patients were switched treatment by their physicians due to the risk of malignancies and infections including PML risk. The proportion of switches that were made due to the risk of PML were 23.9% in the HE DMT and 0.5% in the non-HE DMT groups. The top reasons for switching were relapse frequency (non-HE DMT vs HE-DMT: 26.8% vs 15.2%), lack of efficacy (20.9 vs 11.7) and increased number of MRI lesions (20.3% vs 12.4%). Physicians' risk perception of malignancies and infection excluding PML was not a leading factor when switching treatment. The risk of PML was a key factor, especially for switching patients from HE DMTs. In both groups, lack of efficacy was the key contributing factor for switching. Initiating the treatment with HE DMTs may potentially reduce the number of switches due to sub-optimal efficacy. These findings might help physicians to engage more in discussions with patients about the benefit/risk profile of DMTs. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
177. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone
- Author
-
Martinelli V, Cocco E, Capra R, Salemi G, Gallo P, Capobianco M, Pesci I, Ghezzi A, Pozzilli C, Lugaresi A, Bellantonio P, Amato MP, Grimaldi LM, Trojano M, Mancardi GL, Bergamaschi R, Gasperini C, Rodegher M, Straffi L, Ponzio M, Comi G, Italian Mitoxantrone G.r.o.u.p. COLLABORATORS: Radaelli M, Esposito F, Moiola L, Colombo B, Rossi P, Marrosu MG, Frau J, Lorefice L, Coghe G, Savettieri G, Ragonese P, Cusimano V, Perini P, Rinaldi F, Vidali A, Bertolotto A, Malucchi S, Di Sapio A, Montanari E, Guareschi A, Rizzo A, Zaffaroni M, Baldini S, De Rossi N, Cordioli C, Rasia S, Salvetti M, Buttinelli C, Ausili Cefaro L, De Luca G, Tommaso D, Farina D, Fantozzi R, Ruggieri S, Hakiki B, Zipoli V, Portaccio E, Bartolozzi ML, Scandellari C, Stecchi S, Marchello LP, Palmeri B, Vitello G, Iaffaldano P, Lucchese G, Dattola V, Buccafusca M, Sola P, Simone AM, Barreca F, Patti F, Laisa P, Cavalla P, Masera S, Tavazzi E, Galgani S, Sacco R, Provinciali L, Maura D, LUS, Giacomo, Alfieri G, Ticca A, Piras ML, Maimone D, Bianca M, Iudice A, Giro ME, Galeotti M, Florio C, Spitalieri P, La Mantia L, Motti L, Rottoli MR, Granella F, Solaro C, Scarpini E, Servillo G, Cavalletti G., TEDESCHI, Gioacchino, Martinelli, V, Cocco, E, Capra, R, Salemi, G, Gallo, P, Capobianco, M, Pesci, I, Ghezzi, A, Pozzilli, C, Lugaresi, A, Bellantonio, P, Amato, Mp, Grimaldi, Lm, Trojano, M, Mancardi, Gl, Bergamaschi, R, Gasperini, C, Rodegher, M, Straffi, L, Ponzio, M, Comi, G, COLLABORATORS: Radaelli M, Italian Mitoxantrone G. r. o. u. p., Esposito, F, Moiola, L, Colombo, B, Rossi, P, Marrosu, Mg, Frau, J, Lorefice, L, Coghe, G, Savettieri, G, Ragonese, P, Cusimano, V, Perini, P, Rinaldi, F, Vidali, A, Bertolotto, A, Malucchi, S, Di Sapio, A, Montanari, E, Guareschi, A, Rizzo, A, Zaffaroni, M, Baldini, S, De Rossi, N, Cordioli, C, Rasia, S, Salvetti, M, Buttinelli, C, Ausili Cefaro, L, De Luca, G, Tommaso, D, Farina, D, Fantozzi, R, Ruggieri, S, Hakiki, B, Zipoli, V, Portaccio, E, Bartolozzi, Ml, Scandellari, C, Stecchi, S, Marchello, Lp, Palmeri, B, Vitello, G, Iaffaldano, P, Lucchese, G, Dattola, V, Buccafusca, M, Sola, P, Simone, Am, Barreca, F, Patti, F, Laisa, P, Cavalla, P, Masera, S, Tavazzi, E, Galgani, S, Tedeschi, Gioacchino, Sacco, R, Provinciali, L, Maura, D, Lus, Giacomo, Alfieri, G, Ticca, A, Piras, Ml, Maimone, D, Bianca, M, Iudice, A, Giro, Me, Galeotti, M, Florio, C, Spitalieri, P, La Mantia, L, Motti, L, Rottoli, Mr, Granella, F, Solaro, C, Scarpini, E, Servillo, G, and Cavalletti, G.
- Published
- 2011
178. post marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in intereron beta treatment
- Author
-
TROJANO M, PELLEGRINI F, PAOLICELLI D, FUIANI A, ZIMATORE GB, TORTORELLA C, SIMONE IL, PATTI F, GHEZZI A, PORTACCIO E, ROSSI P, POZZILLI C, SALEMI G, LUGARESI A, BERGAMASCHI R, MILLEFIORINI E, CLERICO M, LUS G, VIANELLO M, AVOLIO C, CAVALLA P, IAFFALDANO P, DIRENZO V, D'ONGHIA M, LEPORE V, LIVREA P, AMATO MP, ITALIAN MULTIPLE SCLEROSIS DATABASE NETWORK GROUP, COMI , GIANCARLO, Trojano, M, Pellegrini, F, Paolicelli, D, Fuiani, A, Zimatore, Gb, Tortorella, C, Simone, Il, Patti, F, Ghezzi, A, Portaccio, E, Rossi, P, Pozzilli, C, Salemi, G, Lugaresi, A, Bergamaschi, R, Millefiorini, E, Clerico, M, Lus, G, Vianello, M, Avolio, C, Cavalla, P, Iaffaldano, P, Direnzo, V, D'Onghia, M, Lepore, V, Livrea, P, Comi, Giancarlo, Amato, Mp, and ITALIAN MULTIPLE SCLEROSIS DATABASE NETWORK, Group
- Published
- 2009
179. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis
- Author
-
Trojano, M., Pellegrini, F., Paolicelli, D., Fuiani, A., Zimatore, G., Tortorella, C., Simone, I., Patti, F., Ghezzi, A., Zipoli, V., Rossi, P., Pozzilli, C., Salemi, G., Lugaresi, A., Bergamaschi, R., Millefiorini, E., Clerico, M., Lus, G., Vianello, M., Avolio, C., Cavalla, P., Lepore, V., Livrea, P., Comi, G., Amato, M., Di Monte, E., Iaffaldano, P., Direnzo, V., D'Onghia, M., Lo Fermo, S., Messina, S., D'Amico, E., Rizzo, A., Zaffaroni, M., Portaccio, E., Martinelli, V., Prosperini, L., Onesti, E., Aridon, P., D'Amelio, M., Ragonese, P., De Luca, G., Farina, D., Di Tommaso, V., Tavazzi, E., Bargiggia, V., Crivelli, P., Cortese, A., Di Rezze, S., Durastanti, V., Alfieri, G., Rosellini, I., Modesto, M., Notariello, M., Tortorella, P., Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Lepore V, Livrea P, Comi G, Amato MP, Di Monte E, Iaffaldano P, Direnzo V, D'Onghia M, Lo Fermo S, Messina S, D'Amico E, Rizzo A, Zaffaroni M, Portaccio E, Martinelli V, Prosperini L, Onesti E, Aridon P, D'Amelio M, Ragonese P, De Luca G, Farina D, Di Tommaso V, Tavazzi E, Bargiggia V, Crivelli P, Cortese A, Di Rezze S, Durastanti V, Alfieri G, Rosellini I, Modesto M, Notariello M, Tortorella P, Trojano, M, Pellegrini, F, Paolicelli, D, Fuiani, A, Zimatore, Gb, Tortorella, C, Simone, Il, Patti, F, Ghezzi, A, Zipoli, V, Rossi, P, Pozzilli, C, Salemi, G, Lugaresi, Alessandra, Bergamaschi, R, Millefiorini, E, Clerico, M, Lus, G, Vianello, M, Avolio, C, Cavalla, P, Lepore, V, Livrea, P, Comi, G, and Amato, Mp
- Subjects
Adult ,Male ,Time Factors ,Multiple Sclerosis ,Interferon beta ,Interferon-beta ,Cohort Studies ,Young Adult ,Multiple Sclerosis, Relapsing-Remitting ,Treatment Outcome ,observational study, multiple sclerosis, interferon, treatment, early ,Sickness Impact Profile ,Multiple Sclerosi ,Quality of Life ,Humans ,Female ,Settore MED/26 - Neurologia ,Prospective Studies ,Follow-Up Studies - Abstract
OBJECTIVE: Recent findings support greater efficacy of early vs. delayed interferon beta (IFNbeta) treatment in patients with a first clinical event suggestive of multiple sclerosis (MS). We aimed to evaluate the effectiveness of early IFNbeta treatment in definite relapsing-remitting MS (RRMS) and to assess the optimal time to initiate IFNbeta treatment with regard to the greatest benefits on disability progression. METHODS: A cohort of 2,570 IFNbeta-treated RRMS patients was prospectively followed for up to 7 years in 15 Italian MS Centers. A Cox proportional hazards regression model adjusted for propensity score (PS) quintiles was used to assess differences between groups of patients with early vs. delayed IFNbeta treatment on risk of reaching a 1-point progression in the Expanded Disability Status Scale (EDSS) score, and the EDSS 4.0 and 6.0 milestones. A set of PS-adjusted Cox hazards regression models were calculated according to different times of treatment initiation (within 1 year up to within 5 years from disease onset). A sensitivity analysis was performed to assess the robustness of findings. RESULTS: The lowest hazard ratios (HRs) for the three PS quintiles-adjusted models were obtained by a cutoff of treatment initiation within 1 year from disease onset. Early treatment significantly reduced the risk of reaching a 1-point progression in EDSS score (HR = 0.63; 95% CI = 0.48-0.85; p < 0.002), and the EDSS 4.0 milestone (HR = 0.56; 95% CI = 0.36-0.90; p = 0.015). Sensitivity analysis showed the bound of significance for unmeasured confounders. INTERPRETATION: Greater benefits on disability progression may be obtained by an early IFNbeta treatment in RRMS.
- Published
- 2009
180. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
- Author
-
Kuhle, J, primary, Disanto, G, additional, Dobson, R, additional, Adiutori, R, additional, Bianchi, L, additional, Topping, J, additional, Bestwick, JP, additional, Meier, U-C, additional, Marta, M, additional, Costa, G Dalla, additional, Runia, T, additional, Evdoshenko, E, additional, Lazareva, N, additional, Thouvenot, E, additional, Iaffaldano, P, additional, Direnzo, V, additional, Khademi, M, additional, Piehl, F, additional, Comabella, M, additional, Sombekke, M, additional, Killestein, J, additional, Hegen, H, additional, Rauch, S, additional, D’Alfonso, S, additional, Alvarez-Cermeño, JC, additional, Kleinová, P, additional, Horáková, D, additional, Roesler, R, additional, Lauda, F, additional, Llufriu, S, additional, Avsar, T, additional, Uygunoglu, U, additional, Altintas, A, additional, Saip, S, additional, Menge, T, additional, Rajda, C, additional, Bergamaschi, R, additional, Moll, N, additional, Khalil, M, additional, Marignier, R, additional, Dujmovic, I, additional, Larsson, H, additional, Malmestrom, C, additional, Scarpini, E, additional, Fenoglio, C, additional, Wergeland, S, additional, Laroni, A, additional, Annibali, V, additional, Romano, S, additional, Martínez, AD, additional, Carra, A, additional, Salvetti, M, additional, Uccelli, A, additional, Torkildsen, Ø, additional, Myhr, KM, additional, Galimberti, D, additional, Rejdak, K, additional, Lycke, J, additional, Frederiksen, JL, additional, Drulovic, J, additional, Confavreux, C, additional, Brassat, D, additional, Enzinger, C, additional, Fuchs, S, additional, Bosca, I, additional, Pelletier, J, additional, Picard, C, additional, Colombo, E, additional, Franciotta, D, additional, Derfuss, T, additional, Lindberg, RLP, additional, Yaldizli, Ö, additional, Vécsei, L, additional, Kieseier, BC, additional, Hartung, HP, additional, Villoslada, P, additional, Siva, A, additional, Saiz, A, additional, Tumani, H, additional, Havrdová, E, additional, Villar, LM, additional, Leone, M, additional, Barizzone, N, additional, Deisenhammer, F, additional, Teunissen, C, additional, Montalban, X, additional, Tintoré, M, additional, Olsson, T, additional, Trojano, M, additional, Lehmann, S, additional, Castelnovo, G, additional, Lapin, S, additional, Hintzen, R, additional, Kappos, L, additional, Furlan, R, additional, Martinelli, V, additional, Comi, G, additional, Ramagopalan, SV, additional, and Giovannoni, G, additional
- Published
- 2015
- Full Text
- View/download PDF
181. Real-life impact of early interferonβ therapy in relapsing multiple sclerosis
- Author
-
Trojano, M1, Pellegrini, F, Paolicelli, D, Fuiani, A, Zimatore, Gb, Tortorella, C, Simone, Il, Patti, F, Ghezzi, A, Zipoli, V, Rossi, P, Pozzilli, C, Salemi, G, Lugaresi, A, Bergamaschi, R, Millefiorini, E, Clerico, M, Lus, G, Vianello, M, Avolio, C, Cavalla, P, Lepore, V, Livrea, P, Comi, G, Amato, Mp, Italian Multiple Sclerosis Database Network (MSDN) Group, Di Monte, E, Iaffaldano, P, Direnzo, V, D'Onghia, M, Lo Fermo, S, Messina, S, D'Amico, E, Rizzo, A, Zaffaroni, M, Portaccio, E, Martinelli, V, Prosperini, L, Onesti, E, Aridon, P, D'Amelio, M, Ragonese, P, De Luca, G, Farina, D, Di Tommaso, V, Tavazzi, E, Bargiggia, V, Crivelli, P, Cortese, A, Di Rezze, S, Durastanti, V, Alfieri, G Rosellini I, Modesto, M, Notariello, M, and Tortorella, P.
- Published
- 2009
182. Serum and cerebrospinal fluid n-acetyl aspartate (NAA) levels in multiple sclerosis (MS) and neuromyelitis optica (NMO)
- Author
-
Tortorella, C, Ruggieri, M, DI MONTE, E, Leante, R, Pica, C, Amato, M, Chezzi, A, Lugaresi, A, Patti, Francesco, Sola, P, Zimatore, G, Iaffaldano, P, Direnzo, V, Ceci, E, Livrea, P, and Trojano, M.
- Published
- 2009
183. CAR.CD123-NK Cells Have an Equally Effective but Safer Off-Tumor/on-Target Profile As Compared to CARCD123-T Cells for the Treatment of Acute Myeloid Leukaemia
- Author
-
Caruso, Simona, Quintarelli, Concetta, De Angelis, Biagio, Del Bufalo, Francesca, Ciccone, Roselia, Donsante, Samantha, Volpe, Gabriele, Manni, Simona, Guercio, Marika, Pezzella, Michele, Iaffaldano, Laura, Silvestris, Domenico Alessandro, Sinibaldi, Matilde, Di Cecca, Stefano, Pitisci, Angela, Velardi, Enrico, Merli, Pietro, Algeri, Mattia, Lodi, Mariachiara, Paganelli, Valeria, Serafini, Marta, Riminucci, Mara, and Locatelli, Franco
- Published
- 2022
- Full Text
- View/download PDF
184. Pressure‐Driven Poiseuille Flow: A Major Component of the Torque‐Balance Governing Pacific Plate Motion
- Author
-
Stotz, I. L., Iaffaldano, G., and Davies, D. R.
- Abstract
The Pacific Plate is thought to be driven mainly by slab pull, associated with subduction along the Aleutians‐Japan, Marianas‐Izu‐Bonin, and Tonga‐Kermadec trenches. This implies that viscous flow within the sub‐Pacific asthenosphere is mainly generated by overlying plate motion (i.e., Couette flow) and that the associated shear stresses at the lithosphere's base are resisting such motion. Recent studies on glacial isostatic adjustment and lithosphere dynamics provide tighter constraints on the viscosity and thickness of Earth's asthenosphere and, therefore, on the amount of shear stress that asthenosphere and lithosphere mutually exchange, by virtue of Newton's third law of motion. In light of these constraints, the notion that subduction is the main driver of present‐day Pacific Plate motion becomes somewhat unviable, as the pulling force that would be required by slabs exceeds the maximum available from their negative buoyancy. Here we use coupled global models of mantle and lithosphere dynamics to show that the sub‐Pacific asthenosphere features a significant component of pressure‐driven (i.e., Poiseuille) flow and that this has driven at least 50% of the Pacific Plate motion since, at least, 15 Ma. A corollary of our models is that a sublithospheric pressure difference as high as ±50 MPa is required across the Pacific domain. Constraints on the viscosity/thickness of the asthenosphere challenge the notion that subduction is the main driver of Pacific Plate motionWe use coupled global models of mantle and lithosphere dynamics to simulate the dynamics of the Pacific Plate since 15 MaResults indicate that a strong Poiseuille (i.e., pressure driven) component of asthenospheric flow drives >50% of the Pacific Plate motion
- Published
- 2018
- Full Text
- View/download PDF
185. Anxiety state affects information processing speed in patients with multiple sclerosis
- Author
-
Goretti, Benedetta, primary, Viterbo, R. G., additional, Portaccio, E., additional, Niccolai, C., additional, Hakiki, B., additional, Piscolla, E., additional, Iaffaldano, P., additional, Trojano, M., additional, and Amato, M. P., additional
- Published
- 2013
- Full Text
- View/download PDF
186. Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial
- Author
-
Amato, MP, primary, Goretti, B, additional, Viterbo, RG, additional, Portaccio, E, additional, Niccolai, C, additional, Hakiki, B, additional, Iaffaldano, P, additional, and Trojano, M, additional
- Published
- 2013
- Full Text
- View/download PDF
187. Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis
- Author
-
Viterbo, R.G., primary, Iaffaldano, P., additional, and Trojano, M., additional
- Published
- 2013
- Full Text
- View/download PDF
188. Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis
- Author
-
Tortorella, C, primary, Romano, R, additional, Direnzo, V, additional, Taurisano, P, additional, Zoccolella, S, additional, Iaffaldano, P, additional, Fazio, L, additional, Viterbo, R, additional, Popolizio, T, additional, Blasi, G, additional, Bertolino, A, additional, and Trojano, M, additional
- Published
- 2013
- Full Text
- View/download PDF
189. Relationships between Plasma Osteopontin Levels and Cognitive Performances in Relapsing Multiple Sclerosis: Effect of Natalizumab Treatment (P04.099)
- Author
-
Iaffaldano, P., primary, Ruggieri, M., additional, Viterbo, R. G., additional, Mastrapasqua, M., additional, Paolicelli, D., additional, Lucchese, G., additional, and Trojano, M., additional
- Published
- 2012
- Full Text
- View/download PDF
190. Cognitive Impairment Is Related to Cerebrospinal Fluid Neurofilament Levels in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis. A Functional MRI Study (P04.104)
- Author
-
Tortorella, C., primary, Romano, R., additional, Ruggieri, M., additional, Direnzo, V., additional, Mastrapasqua, M., additional, Iaffaldano, P., additional, Taurisano, P., additional, Fazio, L., additional, Luciannatelli, E., additional, Popolizio, T., additional, Blasi, G., additional, Bertolino, A., additional, and Trojano, M., additional
- Published
- 2012
- Full Text
- View/download PDF
191. Late Miocene Pacific plate kinematic change explained with coupled global models of mantle and lithosphere dynamics
- Author
-
Stotz, I. L., Iaffaldano, G., and Davies, D. R.
- Abstract
The timing and magnitude of a Pacific plate motion change within the past 10 Ma remains enigmatic, due to the noise associated with finite‐rotation data. Nonetheless, it has been hypothesized that this change was driven by the arrival of the Ontong Java Plateau (OJP) at the Melanesian arc and the consequent subduction polarity reversal. The uncertainties associated with the timing of this event, however, make it difficult to quantitatively demonstrate a dynamical association. Here, we first reconstruct the Pacific plate's absolute motion since the mid‐Miocene (15 Ma), at high‐temporal resolution, building on previous efforts to mitigate the impact of finite‐rotation data noise. We find that the largest change in Pacific plate‐motion direction occurred between 10 and 5 Ma, with the plate rotating clockwise. We subsequently develop and use coupled global numerical models of the mantle/lithosphere system to test hypotheses on the dynamics driving this change. These indicate that the arrival of the OJP at the Melanesian arc, between 10 and 5 Ma, followed by a subduction polarity reversal that marked the initiation of subduction of the Australian plate underneath the Pacific realm, were the key drivers of this kinematic change. Noise‐reduced reconstructions of the Pacific plate's absolute motion since 15 Ma indicate significant Euler pole wander between 10 and 5 MaWe develop coupled global models of mantle and lithosphere dynamics to examine the dynamics underpinning this plate motion changeThe Ontong Java Plateau's arrival at the Melanesian arc and a consequent subduction polarity reversal were the key drivers of this change
- Published
- 2017
- Full Text
- View/download PDF
192. The concurrent emergence and causes of double volcanic hotspot tracks on the Pacific plate
- Author
-
Jones, T. D., Davies, D. R., Campbell, I. H., Iaffaldano, G., Yaxley, G., Kramer, S. C., and Wilson, C. R.
- Abstract
Mantle plumes are buoyant upwellings of hot rock that transport heat from Earth’s core to its surface, generating anomalous regions of volcanism that are not directly associated with plate tectonic processes. The best-studied example is the Hawaiian–Emperor chain, but the emergence of two sub-parallel volcanic tracks along this chain, Loa and Kea, and the systematic geochemical differences between them have remained unexplained. Here we argue that the emergence of these tracks coincides with the appearance of other double volcanic tracks on the Pacific plate and a recent azimuthal change in the motion of the plate. We propose a three-part model that explains the evolution of Hawaiian double-track volcanism: first, mantle flow beneath the rapidly moving Pacific plate strongly tilts the Hawaiian plume and leads to lateral separation between high- and low-pressure melt source regions; second, the recent azimuthal change in Pacific plate motion exposes high- and low-pressure melt products as geographically distinct volcanoes, explaining the simultaneous emergence of double-track volcanism across the Pacific; and finally, secondary pyroxenite, which is formed as eclogite melt reacts with peridotite, dominates the low-pressure melt region beneath Loa-track volcanism, yielding the systematic geochemical differences observed between Loa- and Kea-type lavas. Our results imply that the formation of double-track volcanism is transitory and can be used to identify and place temporal bounds on plate-motion changes.
- Published
- 2017
- Full Text
- View/download PDF
193. Treatment decisions in multiple sclerosis — insights from real-world observational studies
- Author
-
Trojano, Maria, Tintore, Mar, Montalban, Xavier, Hillert, Jan, Kalincik, Tomas, Iaffaldano, Pietro, Spelman, Tim, Sormani, Maria Pia, and Butzkueven, Helmut
- Abstract
The complexity of multiple sclerosis (MS) treatment means that doctors and decision-makers need the best available evidence to make the best decisions for patient care. Randomized controlled trials (RCTs) are accepted as the gold standard for assessing the efficacy and safety of any new drug, but conclusions of these trials do not always aid in daily decision-making processes. Indeed, RCTs are usually conducted in ideal conditions, so can measure efficacy only in restricted and unrepresentative populations. In the past decade, a growing number of MS databases and registries have started to produce long-term outcome data from large cohorts of patients with MS treated with disease-modifying therapies in real-world settings. Such observational studies are addressing issues that are otherwise difficult or impossible to study. In this Review, we focus on the most recently published observational studies designed to identify predictors of poor outcome and treatment response or failure, and to evaluate the relative and long-term effectiveness of currently used MS treatments. We also outline the statistical approaches that are most commonly used to reduce bias and limitations in these studies, and the challenges associated with the use of 'big MS data' to facilitate the implementation of personalized medicine in MS.
- Published
- 2017
- Full Text
- View/download PDF
194. Characterization of morphological, reproductive, and productive performances of Mugellese breed: an update of knowledge
- Author
-
Mannelli, Federica, Franzoni, Alessandro, Galigani, Ilaria, Nistri, Virginia, Daghio, Matteo, Scicutella, Federica, Marzoni, Margherita, Minieri, Sara, Salvucci, Sonia, Cerolini, Silvia, Iaffaldano, Nicolaia, Schiavone, Achille, Cassandro, Martino, Castellini, Cesare, and Buccioni, Arianna
- Abstract
The recovery, safeguarding, and valorization of autochthonous poultry breeds may contribute toward the preservation of animal biodiversity and utilization of marginal lands that otherwise offer little agricultural or industrial value. A key strategy in promoting local breeds involves the characterization of morphological traits and productive performances, which are influenced by the breed's genetic make-up as well as its environment. The Mugellese breed is an Italian local poultry breed originating in the Mugello area of north-east Tuscany. It is characterized by frugality, resilience and resistance to disease, cold, and heat stress. Moreover, these birds are particularly suitable for free-range farming. The Mugellese chicken is described as a dwarf breed with a medium neck, broad shoulders, fairly long and horizontal wings, wide, and well-developed breast (especially in the hen). Over the course of a 1-yr observation and data collection period, involving 23 breeders and 405 adult chickens, the Mugellese breed showed the following performances: 1) a hen-day egg production characterized by 2 major peaks: the first in the spring time (March–April, 65.75%), and the second in the late summer period (August–September, 51.86%); 2) high true fertility values (94.35%) throughout the entire breeding season; 3) a weight gain of 732.44 ± 117.06 g and a feed conversion ratio of 3.94 ± 2.42 at an age of 140 d; 4) a slaughter yield of 77.80% (± 3.91); v) a respective protein, fat, and mineral content in the yolk and albumen were: 27.21 ± 4.21 g, 57.77 ± 1.03 g and 3.47 ± 0.40 g per 100 g of yolk; and 82.50 ± 0.57 g, 0.12 ± 0.01 g and 5.43 ± 0.34 g per 100 g of albumen. More data are needed to validate the data obtained in this trial.
- Published
- 2023
- Full Text
- View/download PDF
195. Allogeneic, donor-derived, second-generation, CD19-CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL
- Author
-
del Bufalo, Francesca, Becilli, Marco, Rosignoli, Chiara, Angelis, Biagio De, Algeri, Mattia, Hanssens, Linda, Gunetti, Monica, Iacovelli, Stefano, Li Pira, Giuseppina, Girolami, Elia, Leone, Giovanna, Lazzaro, Stefania, Bertaina, Valentina, Sinibaldi, Matilde, Di Cecca, Stefano, Iaffaldano, Laura, Künkele, Annette, Boccieri, Emilia, Del Baldo, Giada, Pagliara, Daria, Merli, Pietro, Carta, Roberto, Quintarelli, Concetta, and Locatelli, Franco
- Abstract
F095Allogeneic, donor-derived CD19-CAR T cells can be readily generated for the treatment of pediatric patients with relapsed/refractory BCP-ALLF095Allogeneic CD19-CAR T cells are effective and, compared to autologous CAR, they neither increase toxicity, nor induce high GvHD incidence
- Published
- 2023
- Full Text
- View/download PDF
196. Overview of Turkey Semen Storage: Focus on Cryopreservation – A Review
- Author
-
Iaffaldano, Nicolaia, Di Iorio, Michele, Cerolini, Silvia, and Manchisi, Angelo
- Abstract
This review updates the current state of technologies available for turkey semen storage (hypothermic- liquid storage and cryopreservation), with special attention paid to cryopreservation. Liquid semen can be stored for up to 24 or 48 h at temperatures around 5°C, while cryopreservation allows long-term storage at -196°C. The possibility of using frozen turkey semen for artificial insemination (AI) would have practical benefits for turkey production. Reported fertility rates in response to AI using frozen/thawed semen range from 15.8 to 84.3%. Unsatisfactory fertility may be attributed to an inability of turkey spermatozoa to successfully survive the freezing/thawing process, and this, along with the high variability observed, makes this technique unacceptable for commercial breeding programs. There is therefore a need to standardize the whole freezing and thawing process to improve the post-thaw quality of turkey semen and minimize variability in results. Finding an efficient freezing protocol for turkey semen will allow for the creation of a sperm cryobank, improving current prospects for the commercial use of frozen turkey semen and also for the long-term conservation of the genetic diversity of this bird.
- Published
- 2016
- Full Text
- View/download PDF
197. PO10-TU-23 Osteopontin plasma and cerebrospinal fluid evaluation in multiple sclerosis patients
- Author
-
Ruggieri, M., primary, Pica, C., additional, Tortorella, C., additional, Mastrapasqua, M., additional, Leante, R., additional, Paolicelli, D., additional, Iaffaldano, P., additional, and Trojano, M., additional
- Published
- 2009
- Full Text
- View/download PDF
198. FP21-TU-03 Serum N-acetyl aspartate (NAA) levels differ in multiple sclerosis (MS) and neuromyelitis optica (NMO)
- Author
-
Tortorella, C., primary, Ruggieri, M., additional, Di Monte, E., additional, Pica, C., additional, Ceci, E., additional, Amato, M.P., additional, Ghezzi, A., additional, Lugaresi, A., additional, Patti, F., additional, Sola, P., additional, Zimatore, G.B., additional, Iaffaldano, P., additional, Direnzo, V., additional, Livrea, P., additional, and Trojano, M., additional
- Published
- 2009
- Full Text
- View/download PDF
199. Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial.
- Author
-
Amato, MP, Goretti, B, Viterbo, RG, Portaccio, E, Niccolai, C, Hakiki, B, Iaffaldano, P, and Trojano, M
- Subjects
MULTIPLE sclerosis ,VIRUS diseases ,OCCUPATIONAL training ,INTEREST (Psychology) ,ATTENTION - Abstract
The article discusses a study which was aimed to test a home-based computerized program for retraining attention dysfunction in multiple sclerosis (MS). The study recruited outpatients consecutively referred to the MS Centers of the Universities of Florence and Bari. In its training program, the study detected some improvements exclusively on tasks of sustained attention.
- Published
- 2014
- Full Text
- View/download PDF
200. Role of lithosphere in intra-continental deformation: Central Australia.
- Author
-
Kennett, B.L.N. and Iaffaldano, G.
- Abstract
Abstract: Since the Proterozoic, there has been a set of deformation cycles in central Australia culminating in the Alice Springs Orogeny around 400Ma. These events occurred away from plate boundaries and involved extension as well as compression, although their precise history remains difficult to unravel from the geologic record. Much evidence of deformation is left in the central Australian crust, which features significant Moho topography and an associated gravity signal. In the past, several mechanical models invoked crustal thickening and considerable compression to explain these geophysical characteristics. However, it is hard to envisage extensive deformation affecting the crust alone, but leaving no deformation record in the sub-crustal lithosphere. In recent seismic tomography studies, there is continuous seismically-fast lithosphere in central Australia below depths of about 100km. In this region, the uppermost lithospheric mantle is seismically slow, but exhibits no significant attenuation of seismic waves. These new constraints make simple crustal thickening unlikely to be the main mechanism to generate variations of the Moho depth in central Australia. Here we propose a mechanical model of deformation that involves the entire lithosphere. We make no strong assumptions about the history of deformation cycles. Our model does not require lithospheric thickening at any stage of the deformation cycle, and results in a present-day scenario compatible with shallow as well as deep constraints on the lithosphere structure. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.